ATLANTA, September 9 /PRNewswire/ --

CeloNova BioSciences, Inc. ("CeloNova"), a leading developer of
innovative medical devices, today unveiled the world's first fully
color-coded line of embolic particles, Embozene(TM) Color-Advanced
Microspheres, at the annual meeting of the Cardiovascular and Interventional
Radiology Society of Europe (CIRSE) in Athens, Greece.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070908/CLSA008 )

Embolic microspheres are used to treat liver cancer, fibroids, and other
hypervascularized tumors. "With the release of Color-Advanced Microspheres,
interventional radiologists now have available a highly biocompatible,
precisely calibrated embolic particle that offers the unique safety and
convenience advantages of being color coded by microsphere size. Nothing else
on the embolic market offers such a compelling package of superior clinical
performance combined with total ease-of-use for the physician," stated
CeloNova President and Chief Executive Officer Thomas A. Gordy.

Ranging in size from 40 microns (approximately the diameter of a human
hair) to 900 microns and based on the company's already well-received opaque
microspherical product, Embozene(TM) Color-Advanced Microspheres now offer
the additional benefit of enhanced visibility and instant, effortless
identification of microsphere size by color. This means:

-- Immediate visual confirmation that the microspheres are properly mixed
       before injection;
    -- Reduced risk of cross-contamination during the procedure;
    -- A reduced risk of injecting too many or too few microspheres because
       they are clearly visible;
    -- No more waste due to uncertainty when a physician is operating with
       multiple microsphere sizes.



Gordy continued: "From the beginning, CeloNova has operated on the
principle that our products would be designed with class-leading clinical
outcomes and the real-world needs of physicians and operating room staff in
mind. Embozene(TM) Color-Advanced Microspheres represent the embodiment of
that philosophy in action; color-coding improves patient safety while
simplifying the job of those performing the procedure."

Embozene(TM) Color-Advanced Microspheres are the next evolution in an
embolic platform and are available either in vials or pre-filled syringes
depending on physician preference.

About CeloNova BioSciences, Inc.

Headquartered near Atlanta, Georgia, CeloNova BioSciences, Inc., is a
developer of novel medical devices based on the company's patented
Polyzene(R)-F surface coating technology. Polyzene(R)-F is highly lubricious,
and possesses both anti-bacterial and anti-inflammatory properties that make
it an ideal surface treatment for implanted medical devices. The company's
current product portfolio includes its Embozene(TM) Microspheres, used to
treat arteriovenous malformations, hypervascularized tumors, uterine fibroids
and hepatocellular carcinoma. Other innovative devices are currently in the
company's developmental pipeline. For more information, please visit
www.celonova.com.

Thomas A. Gordy
    President and Chief Executive Officer
    +1-770-502-0304



Web site: http://www.celonova.com